– SWEDEN, Lund – BONESUPPORT, an emerging leader both in injectable bone substitute materials as well as in the innovative drug releasing bone graft technology for orthopedic trauma, bone infections and instrument augmentation in orthopedic surgery, announced today announced that the company has appointed with immediate effect Richard Davies as its new Chief Executive Officer of BONESUPPORT ™. Mr. Davies is a senior commercial executives in the life sciences industry and has 25 years of international experience in all aspects of sales, marketing and country / regional line. He can boast an outstanding track record in the planning and implementation of growth strategies and has delivered successful results in complex situations.

Lloyd Diamond, the current Chief Executive Officer of BONESUPPORT ™, will change with immediate effect in the position of Chief Business Officer. Mr. Diamond will again return to the United States and there establish a presence at management level for the largest market of the company. During his tenure at BONESUPPORT ™ Mr. Diamond was able to conclude Biomet an important distribution agreement in the United States with the largest international entrants room and the company of an organization with an emphasis on research and development into a fully commercial group of companies with more than 20,000 worldwide conducted CERAMENT ™ – Treatments transformed.

“I am proud of the change that BONESUPPORT ™ has taken place from an R & D organization to a global commercial enterprise in the four years during which I was able to afford as CEO my contribution,” said Mr. Diamond. “In my new capacity as Chief Business Officer I can focus on developing the commercial growth of CERAMENT ™, particularly in the US market. “

Mr Davies was previously almost four years as Chief Commercial Officer at Hospira. During this time he has the growth, globalization and modernization across the enterprise forward. Through the use of Mr Davies, the company Hospira has experienced an acceleration of sales growth of 12% per year. Hospira has been taken over by Pfizer late 2015th Prior to his role at Hospira Mr Davies had leadership positions of increasing responsibility at Amgen in Europe, Australia and the United States. His duties included the development of clinical and commercial operations in Central and Eastern Europe, to lead the way for Australia and New Zealand and is responsible for the sales group US Inflammation, marketed Enbrel – the at that time most prescribed biological medicinal products in the United States. His last role at Amgen was as a General Manager for Japan and the Asia-Pacific region. Mr Davies began his career at Eli Lilly, where he spent 13 years in progressively more responsible management positions.

“First I would like Lloyd Diamond, on behalf of the entire Board to express our gratitude for his dedication and his numerous achievements as CEO of BONESUPPORT ™ during the past four years,” said Dr. med. R. Oern Stuge CEO BONESUPPORT ™. “We are delighted to welcome Richard Davies at BONESUPPORT ™. Its enormous pharmaceutical experience will be of central importance in order to exploit the full potential of the drug releasing capacity of CERAMENT ™. I look forward to working closely with Richard Davies, while we focus on the diverse opportunities focus, lying on BONESUPPORT ™ in the years ahead. “

“I am extremely pleased to join BONESUPPORT ™ as CEO, right now, during such an important phase in the company’s history,” Mr Davies said. “The technology developed by BONESUPPORT ™ technology offers significant health benefits for patients and provides for investors significant Value creation potential represents. Lloyd Diamond has done an excellent job for the progress of the company and I am looking forward to working with him and the team to continuously drive this growth. “

Mr Davies is currently Chief Executive Officer of Alvotech Iceland and was formerly a board member of Zydus Hospira Oncology Products Ltd. and several industry associations in Poland and Australia. He holds a degree as a Bachelor of Science in Applied Chemistry from Portsmouth University and an MBA degree from the Warwick Business School.


BONESUPPORT ™ is an emerging leader in injectable bone substitutes for orthopedic trauma focusing on bone infection, instrument augmentation in the field of orthopedic surgery and spinal applications. CERAMENT ™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone. It enables the controlled absorption to future bone ingrowth support and can be injected under local anesthesia for minimally invasive surgery. The unique biological properties of CERAMENT provide a consistent, pre-packaged and ready to use solution for optimum care. CERAMENT ™ | G is the first CE certified, injectable, antibiotic-releasing, ceramic bone substitute material. CERAMENT ™ | G is marked for the promotion and protection of bone healing at Osteomyelitismanagement (bone infection) in CE countries. CERAMENT ™ | G is not available in the US.

CERAMENT ™ is a mature product platform that is commercially available in the US and Europe, and the treatment of bone fragility and other illness or trauma related fractures revolutionized. The scientific research of CERAMENT ™ includes more than eleven years and over forty-five pre-clinical, clinical and animal studies. More than 9,000 patients have been treated with CERAMENT ™. The in Lund, Sweden-based company was founded in 1999 and has offices in the US and in Germany.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>

Comments are closed.